AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17969890
Drug: Pabing Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pabing Recipe 3 (PR3) plus Madopa tablets
Trial: 17969890
Drug: Fixed Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Chinese recipe plus Madopa tablets
Trial: 15889658
Drug: Fuji Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuji Plus with conditioner (10% ferric chloride, 2% citric acid solution)
Trial: 2651472
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (25 mg twice daily for 4 days) + PGE2 (1 mg once or twice)
Trial: 2651472
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (25 mg twice daily for 4 days) + Placebo
Trial: 342679
Drug: Enzyme tablets
RxNorm normalized name: Papaya Enzyme Tablets
DrugBank: Ox bile extract (DB14016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme tablets (mutanase and protease)
Trial: 21626572
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) immediately
Trial: 21626572
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) after 10 weeks
Trial: 16691031
Drug: Immunotherapy (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (n = 41)
Trial: 11781766
Drug: Mixed treatment
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed treatment incorporating both group and individualized treatment
Trial: 11781766
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment only
Trial: 8509313
Drug: Aspirin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (320 mg, three tablets every six hours)
Trial: 8509313
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and placebo (double-blind administration)
Trial: 27119579
Drug: SAR164653 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR164653 (20 to 800 mg single oral doses, repeat doses up to 800 mg)
Trial: 27119579
Drug: SAR164653 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR164653 (single dosing)
Trial: 27119579
Drug: SAR164653 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR164653 (multiple dosing)
Trial: 9002829
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants (subcrestal placement, polished surface sunk by 1 mm)
Trial: 9002829
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants (subcrestal placement)
Trial: 9002829
Drug: Control implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control implants (placed at alveolar crest)
Trial: 9002829
Drug: Modified gingival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified gingival index at 4 months (test implants)
Trial: 1335003
Drug: Treated essential
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated essential hypertensives (propranolol therapy)
Trial: 6704507
Drug: Chlorothiazide administered
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorothiazide administered as a solution
Trial: 6704507
Drug: Chlorothiazide administered
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorothiazide administered as a tablet
Trial: 27291387
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with fractional CO2 laser, targeted UVB phototherapy, and topical 0.05% clobetasol propionate cream
Trial: 27291387
Drug: Targeted UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted UVB phototherapy and topical 0.05% clobetasol propionate cream
Trial: 11983186
Drug: Fluoxetine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (dose stratified from 1.25 mg to 40 mg per day)
Trial: 11983186
Drug: Fluoxetine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (dose response)
Trial: 1771902
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IgIV) (0.4 g/kg during 5 consecutive days, total dose of 2.0 g/kg)
Trial: 1771902
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IgIV)
Trial: 31779620
Drug: Implementation outcomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation outcomes including pAEs, patient/treatment satisfaction, work satisfaction, safety culture, training-related outcomes.
Trial: 29855317
Drug: Life skills
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life skills building education and multiple micronutrient supplementation provided bi-monthly from preconception, twice-weekly during preconception, daily during pregnancy, and daily for 6 months post-partum.
Trial: 29855317
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care including non-regulated community-based health sessions and daily iron and folic acid supplementation during pregnancy.
Trial: 27237018
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient powder (MNP) daily in complementary feeding for 2 months
Trial: 24577485
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg bid and Rivaroxaban
Trial: 20818821
Drug: Bismuth pectin
RxNorm normalized name: bismuth / pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth pectin quadruple therapy (20 mg rabeprazole bid, 1000 mg amoxicillin bid, 100 mg bismuth pectin qid, and 500 mg levofloxacin qd)
Trial: 20818821
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid for 5 d, followed by 20 mg omeprazole bid, 500 mg tinidazole bid, 500 mg clarithromycin bid for another 5 d)
Trial: 20818821
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid, 500 mg clarithromycin bid)
Trial: 15193180
Drug: vax‐SPIRAL vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vax‐SPIRAL vaccine
Trial: 15193180
Drug: Heberbiovac‐HB (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heberbiovac‐HB (control vaccine)
Trial: 9753212
Drug: Azithromycin (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (therapeutic doses) with rifabutin 300 mg/day
Trial: 9753212
Drug: Clarithromycin (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (therapeutic doses) with rifabutin 300 mg/day
Trial: 9753212
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg/day alone
Trial: 3364811
Drug: Etomidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.3 and 0.15 mg.kg‐1 respectively)
Trial: 3364811
Drug: Thiopentone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (3 and 1.5 mg.kg‐1 respectively)
Trial: 25488056
Drug: Saccharomyces cerevisiae
RxNorm normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces cerevisiae (500 mg once daily for 8 weeks)
Trial: 14697066
Drug: Infant orthopedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant orthopedic treatment (IO)
Trial: 14697066
Drug: Non-infant orthopedic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-infant orthopedic treatment (non-IO)
Trial: 10667615
Drug: CCK‐4 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐4 (0.5 mg/60 min)
Trial: 1969198
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg itraconazole daily for 3 to 6 months
Trial: 1969198
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg itraconazole daily for 6 to 8 months
Trial: 1969198
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg itraconazole daily for 6 months
Trial: 1969198
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg itraconazole daily
Trial: 24378762
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) (n = 55); goal setting, problem-solving, and stimulus control
Trial: 23134211
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg/day
Trial: 15047649
Drug: Low-intensity laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity laser therapy (LILT)
Trial: 11496809
Drug: Enuresis alarm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enuresis alarm treatment
Trial: 2557881
Drug: Doxorubicin 60‐75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60‐75 mg m‐2 intravenously once every 3 weeks
Trial: 2557881
Drug: Recombinant alpha
RxNorm normalized name: Recombinant alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha 2 interferon (rIFN) 9‐18 x 10(6) IU m‐2 intramuscularly daily
Trial: 2557881
Drug: Recombinant alpha
RxNorm normalized name: Recombinant alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha 2 interferon (rIFN) 25‐50 x 10(6) IU m‐2 intramuscularly three times weekly
Trial: 31046481
Drug: IL-23/p19 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-23/p19 inhibitors
Trial: 23993130
Drug: Ofloxacin 400mg
RxNorm normalized name: OFLOXACIN 400MG TAB
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400mg twice daily plus Metronidazole 500mg twice daily
Trial: 22232563
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg bevacizumab
Trial: 17326710
Drug: Hypoglycemia induced
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia induced by insulin infusion to nadir levels of 2.2 mmol/l
Trial: 12364470
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH (0.05 mg/kg.d)
Trial: 12364470
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH (0.025 mg/kg.d)
Trial: 12364470
Drug: High-dose GH-IGFBP-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH-IGFBP-3 generation test
Trial: 9845100
Drug: Continuous hyperfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperfractionated accelerated radiation therapy with mitomycin C (V‐CHART + MMC)
Trial: 9845100
Drug: Continuous hyperfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperfractionated accelerated radiation therapy (V‐CHART)
Trial: 7978438
Drug: Clonidine (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (transdermal 0.2 mg/d for 72 h + oral 0.3 mg 60‐90 min before surgery)
Trial: 17631296
Drug: Tesaglitazar (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesaglitazar (0.1, 0.25, 0.5, and 1mg) once daily for 12 weeks
Trial: 16729760
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + bioactive substances in formula CognoBlend (2 capsules twice a day for 5 weeks)
Trial: 15314590
Drug: Subtenons lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subtenons lidocaine injection (1 ml of 2% lidocaine)
Trial: 15314590
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no subtenons lidocaine injection)
Trial: 9294492
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a daily subcutaneous dose of 0.2 or 0.3 IU/kg for 2 years
Trial: 8322989
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of diamorphine added to 4 ml of 0.5% bupivacaine
Trial: 8322989
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% bupivacaine alone
Trial: 29652275
Drug: Ketofol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketofol infusion (ketamine: propofol, 1mg: 3 mg in 20 ml syringe)
Trial: 29652275
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (200 μg in 20 ml normal saline)
Trial: 22687642
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg/day for two months (PIO 15)
Trial: 22687642
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg/day for one month followed by 30 mg/day for an additional one month (PIO 30)
Trial: 10961590
Drug: Budesonide CIR
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide CIR 15 mg
Trial: 10961590
Drug: Budesonide CIR
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide CIR 9 mg
Trial: 9200284
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg, four times daily for 4 weeks
Trial: 3103572
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg of tissue plasminogen activator (rt‐PA)
Trial: 31658051
Drug: Intravenous omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Trial: 22542530
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day) / Ezetimibe (10 mg/day)
Trial: 20087195
Drug: Once-nightly dosing
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-nightly dosing (didanosine plus lamivudine with efavirenz)
Trial: 20087195
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing (combivir with efavirenz)
Trial: 20087195
Drug: Once-nightly dosing
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-nightly dosing
Trial: 18833174
Drug: Transcranial dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial dynamic magnetic therapy (along with basic therapy)
Trial: 9640146
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at 20 vpm
Trial: 9640146
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at 1 vpm
Trial: 9640146
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at 40 vpm
Trial: 9640146
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at 10 vpm
Trial: 7660402
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy in women
Trial: 25700806
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 400 mcg and umeclidinium (UMEC) 500 mcg administered in combination (FF/UMEC 100/125 mcg)
Trial: 31434037
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 100 mcg
Trial: 25700806
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) 125 mcg
Trial: 8357774
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 or 20 mg once daily)
Trial: 3900590
Drug: Verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 80 mg every 8 hours for 5 days
Trial: 24579804
Drug: Dorsal onlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal onlay buccal mucosa graft (BMG) urethroplasty
Trial: 19558428
Drug: Fluconazole cream
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole cream 0.5%
Trial: 19558428
Drug: Fluconazole cream
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole cream 1%
Trial: 19558428
Drug: Flutrimazole cream
RxNorm normalized name: flutrimazole
DrugBank: Flutrimazole (DB13425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutrimazole cream 1%
Trial: 14722144
Drug: H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori eradication treatment (2-week course of omeprazole 20 mg, amoxicillin and clavulanate potassium 750 mg, and metronidazole 400 mg, all twice daily, n = 817)
Trial: 14722144
Drug: H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori eradication treatment (n = 817)
Trial: 9181649
Drug: Loracarbef (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef (200 mg twice daily for 10 days)
Trial: 9181649
Drug: Phenoxymethylpenicillin (800/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin (800/1000 mg twice daily for 10 days)
Trial: 4077772
Drug: 5-nitroimidazole compounds
RxNorm normalized name: 2-methyl-5-nitroimidazole-1-ethanol
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-nitroimidazole compounds (including satranidazole, ronidazole, S75 0400 A)
Trial: 4077772
Drug: Other antiprotozoal
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiprotozoal drugs (berberine sulphate, paromomycin sulphate, erythromycin estolate, sulphasalazine)
Trial: 25770814
Drug: Aprepitant plus
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant plus ondansetron on day 1, followed by aprepitant on days 2 and 3 (125 mg for ages 12-17 years; 3.0 mg/kg up to 125 mg for ages 6 months to <12 years; 80 mg for ages 12-17 years; 2.0 mg/kg up to 80 mg for ages 6 months to <12 years)
Trial: 21591943
Drug: Alemtuzumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (30 mg, one dose)
Trial: 21591943
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (6 mg/kg over 4 days)
Trial: 21591943
Drug: Basiliximab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (40 mg over 4 days)
Trial: 12565779
Drug: Plain aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aqueous gel
Trial: 10874260
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for myocardial infarction
Trial: 9114992
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg once daily
Trial: 30329030
Drug: Measles vaccination
RxNorm normalized name: Measles vaccine (live)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccination in the presence of maternal measles antibodies
Trial: 29949429
Drug: Cabergoline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (3 mg/week)
Trial: 29949429
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg twice daily)
Trial: 27114605
Drug: Cetuximab monotherapy
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab monotherapy (400 mg/m2 loading dose and then 250 mg/m2 once per week)
Trial: 27114605
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus irinotecan (cetuximab 400 mg/m2 loading dose and then 250 mg/m2 once per week with irinotecan 180 mg/m2 once every 2 weeks)